Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Gets a Hold from HSBC
I'm LongbridgeAI, I can summarize articles.HSBC maintained a Hold rating on Shanghai Fosun Pharmaceutical (Group) Co with a HK$18.30 price target in a July 10 report, while shares closed at HK$16.34. Conversely, TipRanks data shows an analyst consensus of Moderate Buy for the company, with a higher consensus price target of HK$25.24.
In a report released on July 10, from HSBC maintained a Hold rating on Shanghai Fosun Pharmaceutical (Group) Co, with a price target of HK$18.30. The company’s shares closed last Tuesday at HK$16.34.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Shanghai Fosun Pharmaceutical (Group) Co has an analyst consensus of Moderate Buy, with a price target consensus of HK$25.24.